Amersham™ ECL™ Prime is a highly sensitive reagent, characterized by stable signal emission, allowing for the possibility of repeated exposures and making it easier to process several blots in the same experimental run. The high intensity of the emitted signals means that proteins can be detected using highly diluted primary and secondary antibodies, contributing to low background and reducing consumption of reagents.
Amersham™ ECL™ Prime consolidates and builds on the benefits of Amersham™ ECL™ Plus and Amersham™ ECL™ Advance to deliver a detection system that is sensitive, stable, precisely quantitative across a wide dynamic range of protein levels, and conservative in its consumption of expensive antibody reagents.
This product or portions thereof is manufactured and sold under license from Cyanagen Srl and is subject of US patent 7,855,287, US Patent 7,803,573, and Italian application number TO2010A000580, together with other equivalent granted patents and patent applications in other countries.
Amersham is a trademark of Cytiva
ECL is a trademark of Cytiva
Rainbow is a trademark of Cytiva